Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01485302 | Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients | PHASE1 | COMPLETED | 48 | — | — | Jan 1, 2012 | Feb 1, 2015 | Mar 25, 2015 | 8 | Bulgaria, France +3 |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dose 1 IV infusion |
| Cohort 2 | EXPERIMENTAL | Dose 2 IV infusion |
| Cohort 3 | EXPERIMENTAL | Dose 3 IV infusion |
| Cohort 4 | EXPERIMENTAL | Dose 4 IV infusion |
| Cohort 5 | EXPERIMENTAL | Dose 1 SC injection |
| Cohort 6 | EXPERIMENTAL | Dose 2 SC injection |
| Name | Type | Description |
|---|---|---|
| SAR228810 | DRUG | Pharmaceutical form:solution Route of administration: intravenous |
Inclusion criteria: * Male or female patients with mild to moderate Alzheimer's disease, aged between 50 and 85 years inclusive * Meets criteria for probable Alzheimer's of the National Institute of Neurologic and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Associ...